Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study
Abstract Introduction The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice. Methods This prospective, observationa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Cardiology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40119-025-00405-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725288239333376 |
|---|---|
| author | Luís Henrique Wolff Gowdak Paulo Magno Martins Dourado Dalton Bertolim Précoma César de Oliviera Lopes Dusilek Francisco Maia da Silva Juan Carlos Yugar-Toledo Felipe Montes Pena Domingos Antônio de Almeida Gomes Elizabeth do Espírito Santo Cestário Olavo Raimundo Guimarães Conrado Roberto Hoffmann Filho Carlos Filinto de Almeida Flávio de Souza Brito Gerez Fernandes Martins Victor Rodrigues Ribeiro Ferreira Marcella Chaves Flores Mayara Lídia da Silva on behalf of the V-GOOD Investigators |
| author_facet | Luís Henrique Wolff Gowdak Paulo Magno Martins Dourado Dalton Bertolim Précoma César de Oliviera Lopes Dusilek Francisco Maia da Silva Juan Carlos Yugar-Toledo Felipe Montes Pena Domingos Antônio de Almeida Gomes Elizabeth do Espírito Santo Cestário Olavo Raimundo Guimarães Conrado Roberto Hoffmann Filho Carlos Filinto de Almeida Flávio de Souza Brito Gerez Fernandes Martins Victor Rodrigues Ribeiro Ferreira Marcella Chaves Flores Mayara Lídia da Silva on behalf of the V-GOOD Investigators |
| author_sort | Luís Henrique Wolff Gowdak |
| collection | DOAJ |
| description | Abstract Introduction The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice. Methods This prospective, observational study involved 1026 adult outpatients with symptomatic CCS from 70 sites in Brazil who were prescribed trimetazidine MR 80 mg OD plus background antianginal treatment. Data on number of angina attacks, short-acting nitrate consumption, prevalence of angina-free patients, severity of angina, patient-reported daily physical activity impairment, treatment adherence, tolerability, and cardiologist and patient satisfaction were collected at baseline (V1), then at 1 month (V2) and 3 months (V3). Results Following the addition of trimetazidine MR 80 mg OD, the mean ± standard deviation number of angina attacks per week decreased from 3.1 ± 2.8 at V1 to 1.0 ± 2.1 at V2, and 0.7 ± 1.7 at V3, with concurrent reductions in short-acting nitrate consumption, patient-reported daily physical activity impairment and the proportion of patients with limiting angina (Canadian Cardiovascular Society class III or IV), and increases in the proportion of angina-free patients (all p < 0.001 vs. V1). Most cardiologists rated trimetazidine MR 80 mg OD as satisfactory/very satisfactory (90.7% for effectiveness and 94.8% for tolerability); most patients rated the treatment schedule as convenient/very convenient (97.2%) and satisfactory/very satisfactory (97.1%). Treatment was well tolerated. Conclusions These data support the symptomatic benefits and good tolerability associated with adding trimetazidine MR 80 mg OD to other antianginal therapies in patients with persistent symptoms. Graphical abstract available for this article. Trial registration number NCT06464276. Graphical Abstract |
| format | Article |
| id | doaj-art-8143b6c00ea04013aba89812050df6c7 |
| institution | DOAJ |
| issn | 2193-8261 2193-6544 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Cardiology and Therapy |
| spelling | doaj-art-8143b6c00ea04013aba89812050df6c72025-08-20T03:10:31ZengAdis, Springer HealthcareCardiology and Therapy2193-82612193-65442025-04-0114224926510.1007/s40119-025-00405-9Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational StudyLuís Henrique Wolff Gowdak0Paulo Magno Martins Dourado1Dalton Bertolim Précoma2César de Oliviera Lopes Dusilek3Francisco Maia da Silva4Juan Carlos Yugar-Toledo5Felipe Montes Pena6Domingos Antônio de Almeida Gomes7Elizabeth do Espírito Santo Cestário8Olavo Raimundo Guimarães9Conrado Roberto Hoffmann Filho10Carlos Filinto de Almeida11Flávio de Souza Brito12Gerez Fernandes Martins13Victor Rodrigues Ribeiro Ferreira14Marcella Chaves Flores15Mayara Lídia da Silva16on behalf of the V-GOOD InvestigatorsInstituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Academic Research OrganizationInstituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Unidade de Hipertensão ExperimentalHospital Angelina CaronlHospital do Rocio, Núcleo de Pesquisa ClínicaPontifícia Universidade Católica do ParanáInstituto de Cardiologia e Endocrinologia São José do Rio PretoUniversidade do Estado do Rio de Janeiro (UERJ)Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Academic Research OrganizationCentro Universitário de VotuporangaSanta Casa de AlfenasCentro Multidisciplinar de Ensino Especializado e PesquisaInstituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Academic Research OrganizationIndacor, Centro de PesquisaInstituto Estadual de Cardiologia Aloysio de CastroBraile CardioLaboratório Servier do BrasilLaboratório Servier do BrasilAbstract Introduction The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice. Methods This prospective, observational study involved 1026 adult outpatients with symptomatic CCS from 70 sites in Brazil who were prescribed trimetazidine MR 80 mg OD plus background antianginal treatment. Data on number of angina attacks, short-acting nitrate consumption, prevalence of angina-free patients, severity of angina, patient-reported daily physical activity impairment, treatment adherence, tolerability, and cardiologist and patient satisfaction were collected at baseline (V1), then at 1 month (V2) and 3 months (V3). Results Following the addition of trimetazidine MR 80 mg OD, the mean ± standard deviation number of angina attacks per week decreased from 3.1 ± 2.8 at V1 to 1.0 ± 2.1 at V2, and 0.7 ± 1.7 at V3, with concurrent reductions in short-acting nitrate consumption, patient-reported daily physical activity impairment and the proportion of patients with limiting angina (Canadian Cardiovascular Society class III or IV), and increases in the proportion of angina-free patients (all p < 0.001 vs. V1). Most cardiologists rated trimetazidine MR 80 mg OD as satisfactory/very satisfactory (90.7% for effectiveness and 94.8% for tolerability); most patients rated the treatment schedule as convenient/very convenient (97.2%) and satisfactory/very satisfactory (97.1%). Treatment was well tolerated. Conclusions These data support the symptomatic benefits and good tolerability associated with adding trimetazidine MR 80 mg OD to other antianginal therapies in patients with persistent symptoms. Graphical abstract available for this article. Trial registration number NCT06464276. Graphical Abstracthttps://doi.org/10.1007/s40119-025-00405-9Angina pectorisChronic coronary syndromeStable anginaTrimetazidine |
| spellingShingle | Luís Henrique Wolff Gowdak Paulo Magno Martins Dourado Dalton Bertolim Précoma César de Oliviera Lopes Dusilek Francisco Maia da Silva Juan Carlos Yugar-Toledo Felipe Montes Pena Domingos Antônio de Almeida Gomes Elizabeth do Espírito Santo Cestário Olavo Raimundo Guimarães Conrado Roberto Hoffmann Filho Carlos Filinto de Almeida Flávio de Souza Brito Gerez Fernandes Martins Victor Rodrigues Ribeiro Ferreira Marcella Chaves Flores Mayara Lídia da Silva on behalf of the V-GOOD Investigators Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study Cardiology and Therapy Angina pectoris Chronic coronary syndrome Stable angina Trimetazidine |
| title | Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study |
| title_full | Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study |
| title_fullStr | Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study |
| title_full_unstemmed | Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study |
| title_short | Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study |
| title_sort | effectiveness and tolerability of trimetazidine 80 mg once daily in patients with chronic coronary syndrome in brazil the v good observational study |
| topic | Angina pectoris Chronic coronary syndrome Stable angina Trimetazidine |
| url | https://doi.org/10.1007/s40119-025-00405-9 |
| work_keys_str_mv | AT luishenriquewolffgowdak effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT paulomagnomartinsdourado effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT daltonbertolimprecoma effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT cesardeolivieralopesdusilek effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT franciscomaiadasilva effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT juancarlosyugartoledo effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT felipemontespena effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT domingosantoniodealmeidagomes effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT elizabethdoespiritosantocestario effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT olavoraimundoguimaraes effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT conradorobertohoffmannfilho effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT carlosfilintodealmeida effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT flaviodesouzabrito effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT gerezfernandesmartins effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT victorrodriguesribeiroferreira effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT marcellachavesflores effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT mayaralidiadasilva effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy AT onbehalfofthevgoodinvestigators effectivenessandtolerabilityoftrimetazidine80mgoncedailyinpatientswithchroniccoronarysyndromeinbrazilthevgoodobservationalstudy |